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B
ecause pregnant women are 
routinely excluded from pre-
licensure clinical trials for fear of 
harming the mother or the developing 
foetus [1], most drugs are marketed 
with limited information on their safety 
during pregnancy and therefore are 
not recommended for use by pregnant 
women. Yet drugs are widely used by 
pregnant women, and medication often 
cannot be avoided in chronic diseases 
such as epilepsy and HIV or other acute 
illness that harm the mother and the 
unborn child if left untreated. 
Passive mechanisms of spontaneous 
reporting of adverse drug effects 
are inadequate for detecting drug-
induced foetal risks or lack of such 
risks [2]. The US Food and Drug 
Administration and the European 
Medicine Agency recommend active 
surveillance, such as the use of 
pregnancy exposure registries (PERs), 
for products that are likely to be 
used during pregnancy or by women 
of childbearing age (WOCBAs), 
particularly if there have been 
case reports of adverse pregnancy 
outcome following exposure, if 
drugs in the same pharmacological 
class are known to pose risk during 
pregnancy, or if pre-clinical animal 
data suggest potential teratogenic 
risk [3,4]. In industrialised countries, 
this information can be derived from 
medical records and automated 
databases, including medical or 
pharmacy insurance claims. Such 
approaches are challenging in 
developing countries where resources 
for routine pharmacovigilance are 
rare and automated data sources 
generally do not exist [5–8]. Thus, 
nearly all developing countries rely on 
drug safety data from industrialised 
countries. However, there are 
often no or limited safety data in 
pregnancy for drugs targeting tropical 
diseases, as these are not widely used 
in the countries with more robust 
pharmacovigilance systems [9]. 
Antimalarials are a good example 
[9]. Malaria can have devastating 
consequences for the mother and 
foetus [10,11], and pregnant women 
require prompt treatment with safe 
and effective antimalarial drugs when 
infected. The artemisinins are among 
the most effective and rapidly acting 
antimalarials to date, providing life-
saving benefits to children, adults, and 
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Summary Points
sÈ 4HEREÈISÈANÈURGENTÈNEEDÈTOÈDEVELOPÈ
targeted pharmacovigilance systems 
to assess the safety of antimalarials in 
early pregnancy. 
sÈ 4HEÈARTEMISININSÈAREÈEFFECTIVEÈ
antimalarials increasingly deployed in 
malaria-endemic countries; however, 
they have been shown to be embryo-
toxic in animal models, and their safety 
in early human pregnancies remains 
uncertain.
sÈ -ODELLINGÈSUGGESTSÈTHATÈTHEÈ
probability an embryo will encounter 
artemisinins during the critical six-
week period (at week four to week 
ten of gestation) through accidental 
exposure is 12% for areas where adults 
receive on average one treatment 
with three days of artemisinin-based 
combination therapy per year. 
sÈ -OSTÈOFÈTHEÈAPPROACHESÈUSEDÈINÈ
industrialised countries to evaluate 
a drug’s embryo-foetal toxicity have 
limited application in resource-poor 
countries. Establishing an international 
antimalarial pregnancy exposure 
registry would enable a targeted 
prospective pharmacovigilance 
approach and timely assessment of the 
risk–benefit profile of antimalarials. 
sÈ (EREÈWEÈDISCUSSÈMETHODOLOGICALÈ
considerations for the systematic 
prospective assessment of 
pregnancy outcomes and congenital 
malformations in women exposed 
to antimalarials early in pregnancy, 
including approaches to capture drug 
exposure information in resource-poor 
settings, choice of comparison groups, 
and sample size considerations. PLoS Medicine  |  www.plosmedicine.org 1311 September 2008  |  Volume 5  |  Issue 9  |  e187
pregnant women [12]. The limited 
information regarding their safety 
is reassuring [13], and the World 
Health Organization (WHO) now 
recommends the use of artemisinin 
combination therapies (ACTs) in the 
second and third but not yet in the 
first trimester (unless alternatives are 
not available) [12], as uncertainty 
remains about their safety in early 
pregnancy (Box 1) [14–16]. ACTs 
are rapidly being rolled out and may 
soon become among the most widely 
used antimalarial drugs. Because 
there are no specific risk management 
precautions to exclude WOCBAs 
from using ACTs, the potential for 
inadvertent exposure to artemisinins 
early in pregnancy is high and in many 
cases unavoidable (Figure 1). Health 
care providers, pregnant women, 
and policy makers urgently need 
valid information to make informed 
decisions about the risks and benefits 
of ACTs for WOCBAs.
This paper describes the use of 
PERs as a targeted pharmacovigilance 
approach for assessing the safety of 
antimalarial drugs used during early 
pregnancy in resource-constrained 
malaria-endemic countries.
Antimalarial Pregnancy Exposure 
Registries
PERs are the most common approach 
used to monitor drug safety in 
pregnancy and provide reassurance 
on the potential risk associated with 
certain drugs. They can serve both to 
generate hypotheses and to evaluate 
suspected risks or risk factors that 
may have been identified during 
pre- or post-marketing phases [2]. In 
industrialised countries, 32 PERs are 
registered with the Food and Drug 
Administration [17]. There is some 
variation in design, but they all use 
prospective approaches and identify 
and follow exposed women until the 
end of pregnancy (i.e., before the 
outcome is known). The systematic 
prospective ascertainment of pregnancy 
outcomes has several major advantages 
over case-control designs and passive 
surveillance. This design reduces 
selection bias (for example, due to 
self-reporting) and recall bias, has the 
potential to use standardised methods 
to assess outcome, and—because of 
the availability of both numerator and 
denominators—allows calculations 
of risk estimates that can then be 
compared against comparison groups 
or background population rates [2]. 
One other attractive feature of PERs 
is that they can be time-limited and 
terminated once the target sample 
size to rule out a pre-defined risk is 
reached.
doi:10.1371/journal.pmed.0050187.g001
Figure 1. Probability that an Embryo Will Encounter Artemisinins Inadvertently During the 
Critical Six-Week Period of Its Development (Week Four to Week Ten), According to the 
Average Number of ACT Treatments Received Per Year
In the figure, χ = number of treatments per year, t = embryo-sensitive period in days (set as 
42 days or six weeks), and p = period of treatment and persistence of drug (set as three days 
because ACTs are normally deployed as a three-day regimen and artemisinins are eliminated 
within hours after each dose). The inadvertently exposed group will consist of women taking 
ACTs for confirmed malaria and for presumed malaria. It has been estimated that over 70% 
of malaria episodes in rural Africa and about 50% in urban areas are self-treated without 
consulting trained professionals [39]. Thus, many of these will be presumptive treatments 
without involvement of the formal health services, diagnostic confirmation of malaria, or 
screening for potential pregnancy. Even if more women seek treatment at health facilities with 
the deployment of more expensive ACTs and rapid diagnostic tests, antimalarials are often 
administered disregarding any diagnostic test. Studies in Africa indicated that between 30% 
and 50% of patients with a negative diagnostic test (microscopy or rapid diagnostic test) were 
still prescribed antimalarial drugs [40,41]. These proportions are likely to increase further when 
successful malaria control reduces malaria exposure. (Adapted from [16].) 
Box 1. Mechanism of 
Artemisinin Toxicity in Early 
Pregnancy
Animal reproductive toxicology studies 
show that artemisinin derivatives all 
have embryo-toxic effects at low-dose 
ranges in all species studied (i.e., mice, 
rat, rabbit, frog, and primate models) 
[31–34].The embryo-toxic mechanism 
is thought to occur through depletion 
of embryonic erythroblasts (primitive 
erythrocytes), which is associated with 
severe anaemia leading to cell damage 
and death due to hypoxia [35]. In 
humans, the most sensitive time window 
may be between week four and week 
ten, when erythroblasts circulate and 
have not yet been fully replaced by 
definitive erythrocytes [36]. In addition 
to the window of sensitivity, the duration 
of exposure is also important. Rodents 
have a synchronous clonal expansion 
of metabolically active erythroblasts, 
making them particularly vulnerable 
during a three- to four-day window early 
in pregnancy. In primates (and most likely 
also in humans), this may not be the case, 
as different generations of erythroblasts 
co-exist and are progressively replaced 
by definitive erythrocytes over a period 
of weeks [35]. In cynomolgus monkeys, 
no embryo lethality or malformations 
were observed with three-day exposures 
(the typical duration of treatment with 
ACTs) or with seven-day exposures 
[31,32,35,36]. The predictive value of the 
animal models for humans is unclear, 
particularly because the duration of daily 
exposure is likely to be short (hours) as 
the artemisinins are rapidly eliminated 
and limited to three or at maximum 
seven days.PLoS Medicine  |  www.plosmedicine.org 1312 September 2008  |  Volume 5  |  Issue 9  |  e187
Assessment of Drug Exposure and 
Record Linkage
The design for reliably capturing 
the occurrence and timing of 
inadvertent drug exposure to ACTs 
in early pregnancy requires special 
consideration. Firstly, the critical 
period occurs around the time when 
many women may not yet be aware 
of their pregnancy (our current 
understanding from animal models 
of the mechanism of embryotoxicity 
of the artemisinins suggests that in 
humans the sensitive drug exposure 
time window is between week four 
to week ten of gestation [Box 1]). 
Secondly, retrospective determination 
of the precise timing of exposure is 
challenging since a typical treatment 
course is short (three days). Another 
difficulty is the accurate assessment 
of the gestational age at the time of 
exposure. Lastly, malaria treatment is 
often home-based or unsupervised and 
antimalarials can be obtained from 
a variety of providers, often over-the-
counter. In contrast, antiretroviral and 
anti-tuberculosis drugs are typically 
provided by formal health services, 
which are more likely to keep records. 
Furthermore, exposures are often long-
term and continuous, making it easier 
to determine if and when a woman 
was exposed to antiretroviral or anti-
tuberculosis medication than with the 
short course of antimalarials.
Although most exposures to 
artemisinins in early pregnancy will be 
unintentional, deliberate exposures can 
occur where the benefit is perceived 
to outweigh the potential risk, as 
recommended by WHO (such as for 
severe life-threatening malaria) [12]. 
Either way, reliable ascertainment 
of drug exposure will require record 
linkage. This can be done using 
prospective approaches by linking 
datasets containing drug dispensing 
information (e.g., malaria treatment 
records from out-patient departments) 
to datasets that capture newly identified 
pregnancies (e.g., from antenatal 
clinics or demographic surveillance 
systems). This can determine whether 
a WOCBA might have been pregnant 
at the time of treatment. Alternatively, 
records of pregnant women can be 
linked retrospectively with their earlier 
treatment records. A disadvantage of 
recruiting pregnant women rather 
than WOCBAs is that miscarriages 
will be missed, as the pregnancy may 
not be sustained long enough for 
women to attend antenatal care. The 
pregnant woman’s drug history should 
be taken to verify the record linkage 
and to capture information on any 
drug use not dispensed through formal 
pharmacies.
Pregnancy Outcome Assessment
The primary outcome of interest 
is a decisive factor for the choice 
of study design, study population, 
and target data sources for outcome 
ascertainment and needs to be defined 
a priori. Although pre-approval 
animal reproductive toxicology studies 
have ambiguous predictive value for 
human embryo-foetal toxicity, due to 
variations in species-specific effects 
[18], the current data from animal 
models suggest that the effects are not 
species-specific and that exposure early 
in the first trimester might cause birth 
defects and/or early embryo/foetal 
death with subsequent miscarriages 
or foetal resorption. Most of the 
existing PERs monitor all pregnancy 
outcomes (i.e., live births, still births, 
and miscarriages), but the design 
and sample size calculation focus on 
capturing birth defects [19]. Foetal 
resorption and early miscarriages are 
very difficult to assess reliably; most will 
go unnoticed clinically as they occur 
before eight to nine weeks, with the 
majority occurring before three weeks 
[20]. Only repeated pregnancy testing 
with a switch from positive to negative 
tests may suggest objectively early loss 
of pregnancy [21]. This is unlikely to 
be feasible or culturally acceptable 
in many malaria-endemic countries, 
and the frequent use of pregnancy 
testing itself reduces the probability 
of inadvertent exposures in that 
population. We may thus have to accept 
that early pregnancy loss cannot be 
captured reliably in sufficient numbers, 
in contrast to later miscarriages and 
stillbirths.
For birth defects, the duration 
of follow-up of the infant needs to 
be considered carefully, since only 
about half of major structural and 
functional defects in children can 
be detected or classified at birth 
[22,23]. The prevalence also varies 
with the specific defect inclusion and 
exclusion criteria and whether the case 
definition includes developmental, 
functional, or other types of congenital 
disorders (e.g., non-structural 
doi:10.1371/journal.pmed.0050187.g002
Figure 2. Sample Size Calculation for Pregnancy Exposure Registry by Defect Frequency and 
Detectable Difference 
Exposed to comparison group ratio = 1:1, power = 80%, and one-sided α = 0.05. Based on the 
formula for cohort design described in Strom’s Pharmacoepidemiology [25]: N = 1/[p(1 −  R)]2 × 
[Z1−α√((1 + 1/k)U(1 − U)) + Z1−β√(pR(1 − Rp) + (P(1 − P))/k)]2 where p is the incidence of disease in 
unexposed; R is the minimum relative risk to detect; k is the ratio of unexposed controls to exposed, 
and U = (Kp + pR)/(k + 1).PLoS Medicine  |  www.plosmedicine.org 1313 September 2008  |  Volume 5  |  Issue 9  |  e187
genetic disorders) [24]. Assessment 
of congenital malformation requires 
careful examination by dedicated staff 
trained to examine newborns using 
a standard tool and scoring system. 
Suspected birth defects could be 
reviewed by a centralised committee 
that included dysmorphologists and 
other specialists (e.g., using digital 
photographs). Complimentary visiting 
specialists could study additional 
outcomes such as cardiovascular and 
neuro-developmental defects and other 
potential long-term effects in a selected 
sample later in infancy.
Comparison Groups
Assessing the teratogenic potential 
of a drug requires comparison of the 
frequency of birth defects against other 
groups to put a signal into context. 
These comparison groups can be 
external (i.e., from peripheral sources) 
or internal (i.e., generated from within 
the same study or system). 
External population data from 
national health statistics centres and/
or birth defects surveillance systems 
are commonly used as sources to 
calculate background event rates. This 
type of external comparison data is not 
currently available in most malaria-
endemic countries. Furthermore, these 
comparisons need to be interpreted 
with caution as many confounding 
factors or potential effect modifiers of 
risk may differ from the exposed group 
of interest [2,25].
Internal comparison groups can 
consist of women with the same 
conditions who are unexposed to 
drugs (in which case the possibility 
of confounding by indication should 
be taken into account), exposed to a 
different drug with established safety, 
or exposed to the same investigational 
drug, but only outside the critical period 
(e.g., in the second or third trimesters). 
Sample Size Calculation
The main determinants of sample size 
are the degree of the teratogenic effect 
to be excluded (relative risk) and the 
expected frequency of the endpoint 
of interest in the non-exposed group 
(Figure 2). A third factor is the type 
and number of potential controls. For 
example, with an exposed/unexposed 
ratio of 1:4, approximately 522 exposed 
women and 2,090 unexposed women 
are needed to exclude a 2-fold increase 
in major malformations detectable 
at birth when the predicted rate in 
the comparison group is 2% (power 
80%, alpha 0.05). This would be 
10,748/42,992 exposed/unexposed 
women for birth defects that occur at a 
frequency of one in 1,000 (such as cleft 
lip/palate). Such numbers will only be 
achievable using several sentinel sites 
over several years. The sample sizes will 
also need to account for loss to follow-
up and the fact that not all births can 
be examined for birth defects (e.g., 
foetal loss with discarding of expelled 
foetus prior to examination by study 
staff). The rate of recruitment will 
depend on the likelihood of accidental 
exposure. This depends on the fertility 
rate and frequency of drug exposure 
in the population. For example, in 
areas where pregnancy testing is not 
available, the average number of ACT 
treatments is one per woman per year, 
and the total fertility rate is 5.5, the 
probability is only 2.5% (or one in 40 
women) (Box 2; see Text S1). 
Concomitant Medication
Although the registry could be set 
up initially to address the specific 
question of the safety of antimalarials 
in pregnancy, it is essential to 
capture concomitant diseases and 
medications such as antiretrovirals 
because of potential drug interactions, 
confounding, and effect modification. 
As such, these additional data could 
contribute to PERs for other diseases 
such as the Antiretroviral Pregnancy 
Registry [26,27].
Data Sources
There are many methodological 
challenges to designing PERs for 
antimalarials, including those 
common to most pharmacovigilance 
methods in resource-poor countries 
[28,29]. The specialised nature of the 
reliable assessment of drug exposure 
and congenital malformations is 
not easily achievable from routine 
pharmacovigilance surveillance systems 
(where they exist). Such an effort will 
require dedicated sentinel sites that 
are capable of following WOCBAs 
and linking antenatal care records 
with treatment records, such as sites 
with demographic health surveillance 
systems or sites with captive populations 
where health care is provided centrally 
and well recorded (e.g., industrial 
and agricultural estates or long-term 
refugee camps). 
An approximation of the probability that a WOCBA attending an out-patient clinic 
has an early pregnancy can be indirectly estimated from published total fertility rates. 
For sub-Saharan Africa, total fertility rate was 5.5 in 2004 [37] and is defined as the 
number of live-born children an average women would have, assuming that she lives 
her full reproductive lifetime of 35 years (1,820 weeks, from 15 to 49 years). The total 
pregnancy rate (6.7) was then calculated as the total fertility rate (5.5) multiplied by a 
factor of 1.22 (1 / [1.0 − 0.15 −  0.03]) to take into account 15% pregnancy loss due to 
miscarriages (a conservative estimate) and 3% due to stillbirths (the average rate of 
stillbirths observed in developing countries [38]). Thus, of 1,820 reproductive weeks, 
a woman is pregnant for 268 weeks (6.7 × 40 weeks); of which 40.2 weeks (6.7 × 6 
weeks) are during the sensitive six-week time window from week four to week ten of 
gestation. Under these conditions, 14.7% (268 of 1,820) of WOCBAs are pregnant at 
any time (i.e., one in 6.8), and 2.2% (40.2 of 1,820) or one in 45 are pregnant between 
week four and week ten. 
If accidental exposure is defined as unintentional treatment in early pregnancy 
only, than the risk of accidental exposure is slightly higher than 2.2%, as later 
pregnancy weeks do not contribute to the denominator. The average time for women 
in Africa to recognise and report a pregnancy is not well described in settings where 
pregnancy testing is not readily available. If it is assumed that this is during the first 
ten weeks of pregnancy, then the denominator is 1,619 weeks (the 1,552 weeks 
that she is not pregnant [1,820 − 268] plus the 67 weeks of early pregnancy (6.7 
pregnancies × 10 weeks), and the risk of accidental exposure in the four- to ten-week 
period is 40.2 out of 1,607 weeks or 2.5% (one in 40 women).
This assumes that the probability of getting clinical malaria is the same in these first 
ten weeks of pregnancy as in non-pregnant women.
Box 2: Probability that a Woman of Childbearing Age Treated for 
Malaria at an Out-Patient Clinic Had an Undetected Pregnancy of 
Four to Ten Weeks GestationPLoS Medicine  |  www.plosmedicine.org 1314 September 2008  |  Volume 5  |  Issue 9  |  e187
While the primary source of 
information is prospective and 
observational, data from clinical trials 
and other studies involving pregnant 
women, and retrospective case series 
(i.e., pregnancies with a known 
outcome at the time of reporting) 
could be included as secondary data 
and analysed separately, as is currently 
done with some of the existing PERs 
[30].
Conclusion
The establishment of an international 
antimalarial pregnancy exposure 
registry, using specialised sentinel 
sites to provide reliable exposure and 
outcome data for the primary data 
collection, is a potentially cost-effective 
targeted approach. Central collation 
of the information would enable 
evaluation of the risk–benefit profile of 
antimalarials in a timely manner, and 
over time would allow the detection of 
rare adverse drug reactions that could 
not be detected by any single study. 
New levels of collaboration between 
pharmacovigilance programmes, 
antimalarial drug developers, research 
groups, regulatory authorities, 
and WHO will be essential. This 
international multi-product, multi-
sponsor approach will require 
good governance structures, such 
as those used by the Antiretroviral 
Pregnancy Registry, and if successful 
could serve as a pathfinder for other 
PERs to capture much-needed safety 
information on other drugs used for 
tropical diseases [9].  
Supporting Information
Text S1. A longer, more detailed version of 
this paper
Found at doi:10.1371/journal.
pmed.0050187.sd001 (596 KB DOC).
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